Article

Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease.

Département de Pneumologie, Hôpitaux Universitaries de Strasbourg, France.
Proceedings of the American Thoracic Society 02/2008; 5(2):237-41. DOI: 10.1513/pats.200706-077MG
Source: PubMed

ABSTRACT Chronic obstructive pulmonary disease (COPD) and sleep apnea-hypopnea syndrome (SAHS) are both common diseases affecting respectively 10 and 5% of the adult population over 40 years of age, and their coexistence, which is denominated overlap syndrome, can be expected to occur in about 0.5% of this population. A recent epidemiologic study has shown that the prevalence of SAHS is not higher in COPD than in the general population, and that the coexistence of the two conditions is due to chance and not through a pathophysiologic linkage between these two diseases. Patients with overlap have a more important sleep-related O(2) desaturation than do patients with COPD with the same degree of bronchial obstruction. They have an increased risk of developing hypercapnic respiratory insufficiency and pulmonary hypertension when compared with patients with SAHS alone and with patients with "usual" COPD. In patients with overlap, hypoxemia, hypercapnia, and pulmonary hypertension can be observed in the presence of mild to moderate bronchial obstruction, which is different from "usual" COPD. Therapy of the overlap syndrome consists of nasal continuous positive airway pressure or nocturnal noninvasive ventilation (NIV), with or without associated nocturnal O(2). Patients who are markedly hypoxemic during daytime (Pa(O(2)) < 55-60 mm Hg) should be given conventional long-term O(2) therapy in addition to nocturnal ventilation.

6 Followers
 · 
241 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic inflammation is associated with chronic obstructive pulmonary disease (COPD) and many other chronic diseases. It is increasingly recognized that individuals with COPD frequently have underlying comorbidities including cardiovascular disease, skeletal muscle dysfunction, depression and anxiety, obstructive sleep apnea, osteoporosis, gastroesophageal reflux disease, anemia, lung cancer, cognitive impairment, diabetes, renal insufficiency, and chronic infections. The link between systemic inflammation, COPD, and its common comorbidities is incompletely understood. However, persons with COPD and comorbidities have a reduced quality of life and functional status, utilize more health care resources, and are at higher risk of hospitalization and death. Screening for and treating comorbidities are important in the integrated care of the COPD patient and may have a substantial impact on morbidity and mortality.
    Clinical Pulmonary Medicine 01/2014; 21(4):155-166. DOI:10.1097/CPM.0000000000000044
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overlap syndrome between obstructive sleep apnoea (OSA) and chronic obstructive pulmonary disease (COPD) is important but under-recognised. We aimed to determine the prevalence of overlap syndrome and the predictors of OSA in patients with COPD.
    Singapore medical journal 09/2014; 55(9):488-92. DOI:10.11622/smedj.2014117 · 0.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a general concern that hypnotic medications in patients with respiratory disorders have the potential to decrease respiratory effort and blunt the arousal response to hypoxemia which may lead to sleep breathing disorders. We investigated whether suvorexant, an orexin receptor antagonist approved for treatment of insomnia at a maximum daily dose of 20 mg in the US, causes sleep breathing disorders in patients with chronic obstructive pulmonary disease (COPD). This was a randomized, double-blind, placebo-controlled, 2-period, cross-over, study performed in 9 sleep laboratories/clinical research units in the United States. The participants were 25 COPD patients aged 39-72 y with mild-to-moderate airflow limitation based on GOLD spirometry criteria. In each period, patients received suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds) or placebo for four consecutive nights. Respiratory function during sleep was measured by oxygen saturation using pulse oximetry (SpO2, primary endpoint) and Apnea Hypopnea Index (AHI, secondary endpoint). The study was powered to rule out a difference between treatments of -2 percentage points in SpO2 on Day 4. There was no treatment effect following single and multiple doses of suvorexant on mean SpO2 during total sleep time (Day 1: suvorexant = 93.14%, placebo = 93.24%, difference = -0.10 [90% CI: -0.50, 0.31]; Day 4: suvorexant = 93.38%, placebo = 92.99%, difference = 0.39 [90% CI: -0.12, 0.91]). There was no clinically meaningful increase in mean AHI by suvorexant compared with placebo on Day 1 (difference = 0.72 [90% CI: -0.60, 2.04]) or Day 4 (difference = 2.05 [90% CI: 0.33, 3.77]). These data do not suggest an overt respiratory depressant effect with 30-40 mg daily doses of suvorexant, up to twice the maximum recommended dose for treating insomnia in the US, in patients with mild-to-moderate COPD. Trial registration Clinicaltrials.gov identifier: NCT01293006. Copyright © 2015. Published by Elsevier Ltd.
    Respiratory Medicine 01/2015; 109(3). DOI:10.1016/j.rmed.2014.12.010 · 2.92 Impact Factor